Prokarium is leveraging the evolutionary advantages of a proprietary strain of Salmonella as a microbial immunotherapy platform

  • Naturally tumor targeting and oncolytic
  • Overcomes the suppressive tumor microenvironment
  • Targets multiple pathways to elicit strong anti-tumor immunity
  • Extensive opportunities to deliver diverse cargo

BLADDER CANCER​

PARADIGM, [RE]DESIGNED

Transforming the treatment paradigm in the
costliest cancer to become the new standart-of-care in a market that has seen little innovation in >30 years

IMMUNOTHERAPY (IO) PRIME

FITNESS, [RE]STORED

Restoring anti-tumor responses with an oral immune training agent to boost efficacy of immunotherapies for the 80% of patients unable to benefit today

PLATFORM

EVOLUTION, [RE]PROGRAMMED

Reprogramming Salmonella with bespoke synthetic circuits to deliver diverse therapeutic cargo for difficult-to-treat cancers

BLADDER CANCER

PARADIGM, [RE]DESIGNED

Bladder cancer is one of the costliest cancers to treat with 550.000 new cases annually worldwide, representing 5% of all new cases in the US. The clinical staging is determined by the depth of tumor invasion into the bladder wall and more than 70% of patients are diagnosed at an early stage, known as non-muscle invasive bladder cancer (NMIBC). Despite early diagnosis, and treatment with standard-of-care Bacillus Calmette-Guerin (BCG), up to 80% of patients recur increasing the risk of progression. Because of bladder cancer’s high incidence, frequent recurrences, and low number of treatment options, a huge unmet medical need remains.

ABOUT US

PIPELINE

Indication

Discovery

Preclinical

IND-enabling

Phase 1

Phase 2

NMIBC

Discovery

Preclinical

IND-enabling

Phase 1

Phase 2

Lead oncology program entering the clinic in the US in H2 2023 

Indication

IO Prime

Discovery

Preclinical

IND-enabling

Phase 1

Phase 2

First-in-class oral training agent ready to enter the clinic in late-2023
Seeking partnership and licensing opportunities to combine with advanced immunotherapies

Indication

Solid tumours 

Discovery

Preclinical

IND-enabling

Phase 1

Phase 2

Discovery cargo-delivery platform

Indication

Enteric Fever

Discovery

Preclinical

IND-enabling

Phase 1

Phase 2

Oral, bivalent vaccine funded by Wellcome Trust

London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – March 2, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
LONDON, UK – November 11, 2021– Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today...
LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – November 2, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial...
London / Amsterdam – October 12, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial...
LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – October 5, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
LONDON, UK – July 27, 2021 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Entervax is a novel bivalent oral vaccine against enteric fever, currently in a phase 1 trial with the...
Entervax is a novel bivalent oral vaccine against enteric fever, currently in a phase 1 trial with the...
– Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of Directors – Financing will support the clinical...
– Industry veteran, Hyam Levitsky, MD, appointed to Prokarium’s Board of Directors – Financing will support the clinical...
Prokarium welcomes Hyam Levitsky and David Holden as new advisors.
Prokarium welcomes Hyam Levitsky and David Holden as new advisors.
Livija Deban, Prokarium’s CSO, will be presenting at CICON23 Title: IO Prime: Restoring Immune Fitness with Oral Salmonella...
Kristen Albright, Prokarium’s CEO, will be attending the 23rd Annual Biotech in Europe Forum from 20-21 September 2023...
Marc Biarnes Carrera, Prokarium’s Head, Discovery, Synthetic Biology, poster presentation at SynBioBetaTitle: A pipeline for the evolution and...
Kristen Albright, Prokarium’s CEO, will be attending the 9th Annual LSX World Congress from 3-4 May 2023 in...

Design the future with us

Icons